Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Show more

40 Erie Street, Cambridge, MA, 02139, United States

https://www.intelliatx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.507B

52 Wk Range

$5.90 - $28.25

Previous Close

$12.76

Open

$13.05

Volume

3,707,821

Day Range

$12.88 - $13.66

Enterprise Value

1.151B

Cash

449.9M

Avg Qtr Burn

-69.29M

Insider Ownership

4.61%

Institutional Own.

85.57%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lonvoguran ziclumeran (lonvo-z) (NTLA-2002) Details Hereditary angioedema (HAE)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
nexiguran ziclumeran (nex-z) (NTLA-2001) Details ATTR amyloidosis with polyneuropathy (ATTRv-PN)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
nexiguran ziclumeran (nex-z) (NTLA-2001) Details Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Phase 3 Re-initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NTLA-5001 Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NTLA-3001 Details Alpha-1 Antitrypsin Deficiency, Lung disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTQ923 / HIX763 (Hematopoietic Stem Cells (HSC)) Details Sickle cell disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.